Chromadex Corp (NASDAQ: CDXC) has a higher price-to-earnings ratio of 409.48x compared to its average ratio. CDXC has 36-month beta value of 2.02. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CDXC is 48.21M, and currently, short sellers hold a 5.40% ratio of that float. The average trading volume of CDXC on November 21, 2024 was 1.09M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CDXC) stock’s latest price update
Chromadex Corp (NASDAQ: CDXC)’s stock price has surge by 3.19relation to previous closing price of 7.50. Nevertheless, the company has seen a 7.49% surge in its stock price over the last five trading sessions. zacks.com reported 2024-11-21 that ChromaDex (CDXC) made it through our “Recent Price Strength” screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
CDXC’s Market Performance
Chromadex Corp (CDXC) has experienced a 7.49% rise in stock performance for the past week, with a 123.67% rise in the past month, and a 120.49% rise in the past quarter. The volatility ratio for the week is 6.90%, and the volatility levels for the past 30 days are at 9.79% for CDXC. The simple moving average for the last 20 days is 27.79% for CDXC stock, with a simple moving average of 131.10% for the last 200 days.
Analysts’ Opinion of CDXC
B. Riley Securities, on the other hand, stated in their research note that they expect to see CDXC reach a price target of $2.40, previously predicting the price at $6. The rating they have provided for CDXC stocks is “Neutral” according to the report published on August 11th, 2022.
ROTH Capital gave a rating of “Buy” to CDXC, setting the target price at $7 in the report published on March 08th of the previous year.
CDXC Trading at 70.68% from the 50-Day Moving Average
After a stumble in the market that brought CDXC to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.90% of gains for the given period.
Volatility was left at 9.79%, however, over the last 30 days, the volatility rate increased by 6.90%, as shares surge +122.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +118.25% upper at present.
During the last 5 trading sessions, CDXC rose by +6.09%, which changed the moving average for the period of 200-days by +396.01% in comparison to the 20-day moving average, which settled at $6.05. In addition, Chromadex Corp saw 441.20% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDXC starting from Patrick Kristin, who sale 23,000 shares at the price of $3.57 back on Aug 23 ’24. After this action, Patrick Kristin now owns 0 shares of Chromadex Corp, valued at $82,110 using the latest closing price.
Kristin Patrick, the affiliate of Chromadex Corp, proposed sale 23,000 shares at $3.69 during a trade that took place back on Aug 23 ’24, which means that Kristin Patrick is holding shares at $84,810 based on the most recent closing price.
Stock Fundamentals for CDXC
Current profitability levels for the company are sitting at:
- 0.02 for the present operating margin
- 0.56 for the gross margin
The net margin for Chromadex Corp stands at 0.01. The total capital return value is set at 0.06. Equity return is now at value 4.82, with 2.70 for asset returns.
Based on Chromadex Corp (CDXC), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 4.02.
Currently, EBITDA for the company is -3.89 million with net debt to EBITDA at -15.16. When we switch over and look at the enterprise to sales, we see a ratio of 5.62. The receivables turnover for the company is 14.23for trailing twelve months and the total asset turnover is 1.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.95.
Conclusion
To put it simply, Chromadex Corp (CDXC) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
